In the case of a subset of high-grade serous ovarian carcinoma patients with p53 aggregation, poor chemo-response was observed again, suggesting p53 aggregation as a new marker for chemoresistance [91]. This evidence concerns the gene TP53 and ovarian serous carcinoma.